MX2017010129A - Inmunomoduladores. - Google Patents
Inmunomoduladores.Info
- Publication number
- MX2017010129A MX2017010129A MX2017010129A MX2017010129A MX2017010129A MX 2017010129 A MX2017010129 A MX 2017010129A MX 2017010129 A MX2017010129 A MX 2017010129A MX 2017010129 A MX2017010129 A MX 2017010129A MX 2017010129 A MX2017010129 A MX 2017010129A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- immunomodulators
- amelioration
- inhibit
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente descripción proporciona péptidos macrocíclicos novedosos que inhiben las interacciones proteína/proteína PD-1/PD-L1 y PD-L1/CD80, y por ende, son útiles para la mejora de distintas enfermedades, que incluyen el cáncer y las enfermedades infecciosas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562111900P | 2015-02-04 | 2015-02-04 | |
PCT/US2016/016074 WO2016126646A1 (en) | 2015-02-04 | 2016-02-02 | Immunomodulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017010129A true MX2017010129A (es) | 2017-11-01 |
Family
ID=55538582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017010129A MX2017010129A (es) | 2015-02-04 | 2016-02-02 | Inmunomoduladores. |
Country Status (16)
Country | Link |
---|---|
US (2) | US20160222060A1 (es) |
EP (1) | EP3253775B1 (es) |
JP (1) | JP6726195B2 (es) |
KR (1) | KR20170109644A (es) |
CN (1) | CN107207568B (es) |
AR (1) | AR105053A1 (es) |
AU (1) | AU2016215543A1 (es) |
BR (1) | BR112017016039A2 (es) |
CA (1) | CA2975716A1 (es) |
EA (1) | EA201791708A1 (es) |
ES (1) | ES2937286T3 (es) |
IL (1) | IL253745A0 (es) |
MX (1) | MX2017010129A (es) |
SG (1) | SG11201706194UA (es) |
TW (1) | TW201636359A (es) |
WO (1) | WO2016126646A1 (es) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2928474T3 (pl) | 2012-12-07 | 2019-05-31 | Chemocentryx Inc | Laktamy diazolowe |
KR102330652B1 (ko) | 2014-09-11 | 2021-11-23 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 및 cd80 (b7-1)/pd-li 단백질/단백질 상호작용의 마크로시클릭 억제제 |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
TWI808938B (zh) | 2016-04-07 | 2023-07-21 | 美商卡默森屈有限公司 | 藉由投予ccr1拮抗劑與pd-1抑制劑或pd-l1抑制劑之組合減少腫瘤負荷 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
EP3827849A1 (en) | 2016-05-19 | 2021-06-02 | Bristol-Myers Squibb Company | Pet-imaging immunomodulators |
ES2913233T3 (es) * | 2016-09-13 | 2022-06-01 | Daiichi Sankyo Co Ltd | Péptido de unión a trombospondina 1 |
KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
CN110267971B (zh) * | 2016-11-07 | 2023-12-19 | 百时美施贵宝公司 | 免疫调节剂 |
MX2019007615A (es) | 2016-12-23 | 2019-11-05 | Univ Johns Hopkins | Imagenología de celulas tumorales e inmunitarias basadas en expresion de pd-l1. |
US11066445B2 (en) | 2017-06-23 | 2021-07-20 | Bristol-Myers Squibb Company | Immunomodulators acting as antagonists of PD-1 |
US20210130467A1 (en) * | 2017-08-17 | 2021-05-06 | Nektar Therapeutics | Immunotherapeutic tumor treatment method |
KR20200110300A (ko) | 2017-09-25 | 2020-09-23 | 케모센트릭스, 인크. | 케모카인 수용체 2(ccr2) 길항제 및 pd-1/pd-l1 억제제를 사용하는 병용 요법 |
KR20200058506A (ko) * | 2017-10-03 | 2020-05-27 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
WO2019117690A1 (ko) | 2017-12-15 | 2019-06-20 | 경북대학교 산학협력단 | Pd-l1에 결합하는 펩타이드 및 이의 용도 |
KR102150419B1 (ko) | 2017-12-15 | 2020-09-01 | 경북대학교 산학협력단 | Pd-l1에 결합하는 펩타이드 및 이의 용도 |
WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
KR102492115B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드 |
EP3737367A4 (en) | 2018-01-08 | 2022-11-09 | ChemoCentryx, Inc. | METHODS OF TREATING SOLID TUMORS USING CCR2 ANTAGONISTS |
CN108409830B (zh) * | 2018-02-05 | 2021-04-23 | 郑州大学 | 一种人pd-1蛋白胞外段亲和环肽c8及其应用 |
IL300572A (en) | 2018-02-13 | 2023-04-01 | Gilead Sciences Inc | PD–1/PD–L1 inhibitors |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
AU2019247905B2 (en) | 2018-04-06 | 2023-10-05 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
TW202017569A (zh) | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
JP7388635B2 (ja) | 2018-05-31 | 2023-11-29 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬の有効性判定バイオマーカー |
PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
TW202028212A (zh) | 2018-10-11 | 2020-08-01 | 日商小野藥品工業股份有限公司 | Sting促效化合物 |
AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
EP3946625A1 (en) | 2019-03-28 | 2022-02-09 | Bristol-Myers Squibb Company | Methods of treating tumor |
KR20210146349A (ko) | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
KR20220010535A (ko) * | 2019-05-21 | 2022-01-25 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
JP2022534967A (ja) | 2019-05-30 | 2022-08-04 | ブリストル-マイヤーズ スクイブ カンパニー | 多腫瘍遺伝子シグネチャーおよびその使用 |
EP3976832A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
JP2022534981A (ja) | 2019-05-30 | 2022-08-04 | ブリストル-マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよび組み合わせ治療 |
WO2021025031A1 (ja) | 2019-08-05 | 2021-02-11 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬の有効性判定バイオマーカー |
AU2020350795A1 (en) | 2019-09-22 | 2022-03-31 | Bristol-Myers Squibb Company | Quantitative spatial profiling for LAG-3 antagonist therapy |
BR112022008191A2 (pt) | 2019-11-08 | 2022-07-12 | Bristol Myers Squibb Co | Terapia com antagonista de lag-3 para melanoma |
WO2021202501A1 (en) * | 2020-03-30 | 2021-10-07 | Bristol-Myers Squibb Company | Immunomodulators |
EP4134134A4 (en) | 2020-04-10 | 2023-12-27 | ONO Pharmaceutical Co., Ltd. | STING AGONIST COMPOUND |
KR20220167275A (ko) | 2020-04-10 | 2022-12-20 | 오노 야꾸힝 고교 가부시키가이샤 | 암 치료 방법 |
CN113754736A (zh) * | 2020-06-02 | 2021-12-07 | 南京礼威生物医药有限公司 | 含酰肼结构的pd-l1环肽抑制剂 |
WO2022047189A1 (en) | 2020-08-28 | 2022-03-03 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
EP4204453A1 (en) | 2020-08-31 | 2023-07-05 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
US20230381112A1 (en) | 2020-09-22 | 2023-11-30 | Vaccitech North America, Inc. | Compositions and Methods of Manufacturing Amphiphilic Block Copolymers that Form Nanoparticles in Situ |
US20240101666A1 (en) | 2020-10-23 | 2024-03-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
IL307262A (en) | 2021-03-29 | 2023-11-01 | Juno Therapeutics Inc | METHODS FOR DOSAGE AND THERAPY IN COMBINATION OF CHECKPOINT INHIBITOR AND CAR T CELL THERAPY |
CN117425666A (zh) * | 2021-06-09 | 2024-01-19 | 百时美施贵宝公司 | 环肽免疫调节剂 |
AU2022290855A1 (en) | 2021-06-11 | 2023-12-07 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
AU2022375806A1 (en) | 2021-10-29 | 2023-12-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
WO2023196964A1 (en) | 2022-04-08 | 2023-10-12 | Bristol-Myers Squibb Company | Machine learning identification, classification, and quantification of tertiary lymphoid structures |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
US6277818B1 (en) | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
CN105315373B (zh) | 2005-05-09 | 2018-11-09 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
JP5605602B2 (ja) | 2007-03-26 | 2014-10-15 | 国立大学法人 東京大学 | 環状ペプチド化合物の合成方法 |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
WO2010027828A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
JP5818237B2 (ja) | 2010-09-09 | 2015-11-18 | 国立大学法人 東京大学 | N−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
US10195578B2 (en) | 2010-12-03 | 2019-02-05 | The University Of Tokyo | Peptide library production method, peptide library, and screening method |
CN103732238A (zh) * | 2011-06-08 | 2014-04-16 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的治疗性化合物 |
WO2013144704A1 (en) | 2012-03-29 | 2013-10-03 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the bc loop of human pd1 |
ES2647076T3 (es) | 2012-06-06 | 2017-12-19 | Polyphor Ag | Peptidomiméticos de horquilla beta |
JP2013253842A (ja) | 2012-06-06 | 2013-12-19 | Univ Of Tokyo | pH依存的に標的分子に結合するペプチドのスクリーニング方法 |
KR20230070054A (ko) | 2013-03-15 | 2023-05-19 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
PL3041468T3 (pl) | 2013-09-06 | 2018-12-31 | Aurigene Discovery Technologies Limited | Pierścieniowe związki peptydomimetyczne jako immunomodulatory |
WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
KR102330652B1 (ko) | 2014-09-11 | 2021-11-23 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 및 cd80 (b7-1)/pd-li 단백질/단백질 상호작용의 마크로시클릭 억제제 |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
-
2016
- 2016-02-01 US US15/011,829 patent/US20160222060A1/en not_active Abandoned
- 2016-02-02 SG SG11201706194UA patent/SG11201706194UA/en unknown
- 2016-02-02 MX MX2017010129A patent/MX2017010129A/es unknown
- 2016-02-02 ES ES16710344T patent/ES2937286T3/es active Active
- 2016-02-02 AU AU2016215543A patent/AU2016215543A1/en not_active Abandoned
- 2016-02-02 EA EA201791708A patent/EA201791708A1/ru unknown
- 2016-02-02 CN CN201680008281.2A patent/CN107207568B/zh active Active
- 2016-02-02 CA CA2975716A patent/CA2975716A1/en not_active Abandoned
- 2016-02-02 EP EP16710344.9A patent/EP3253775B1/en active Active
- 2016-02-02 BR BR112017016039A patent/BR112017016039A2/pt not_active Application Discontinuation
- 2016-02-02 JP JP2017541039A patent/JP6726195B2/ja active Active
- 2016-02-02 WO PCT/US2016/016074 patent/WO2016126646A1/en active Application Filing
- 2016-02-02 KR KR1020177024283A patent/KR20170109644A/ko not_active Application Discontinuation
- 2016-02-03 TW TW105103604A patent/TW201636359A/zh unknown
- 2016-02-03 AR ARP160100309A patent/AR105053A1/es unknown
-
2017
- 2017-03-21 US US15/465,218 patent/US10450347B2/en active Active
- 2017-07-31 IL IL253745A patent/IL253745A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA201791708A1 (ru) | 2017-12-29 |
ES2937286T3 (es) | 2023-03-27 |
TW201636359A (zh) | 2016-10-16 |
KR20170109644A (ko) | 2017-09-29 |
BR112017016039A2 (pt) | 2018-03-20 |
CN107207568A (zh) | 2017-09-26 |
WO2016126646A1 (en) | 2016-08-11 |
CA2975716A1 (en) | 2016-08-11 |
US10450347B2 (en) | 2019-10-22 |
JP2018507197A (ja) | 2018-03-15 |
US20170283462A1 (en) | 2017-10-05 |
JP6726195B2 (ja) | 2020-07-22 |
CN107207568B (zh) | 2021-12-10 |
SG11201706194UA (en) | 2017-08-30 |
EP3253775B1 (en) | 2022-11-23 |
AR105053A1 (es) | 2017-09-06 |
EP3253775A1 (en) | 2017-12-13 |
IL253745A0 (en) | 2017-09-28 |
US20160222060A1 (en) | 2016-08-04 |
AU2016215543A1 (en) | 2017-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017011960A (es) | Inmunomoduladores. | |
MX2017010129A (es) | Inmunomoduladores. | |
MX2017007677A (es) | Inmunomoduladores. | |
MX2017004542A (es) | Inmunomoduladores. | |
MX2018010414A (es) | Inmunomoduladores. | |
PH12017500441A1 (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions | |
MX2017008160A (es) | Inmunomoduladores. | |
PH12017500858A1 (en) | Mocrocyclic peptides useful as immunomodulators | |
MX2018012039A (es) | Inhibidores macrociclicos de interacciones proteina/proteina de proteina de muerte programada 1/ligando de muerte programada 1 (pd-1/pd-l1) y cumulo de diferenciacion 80/ ligando de muerte programada 1 (cd80/pd-l1). | |
PH12015502027A1 (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1) / pd-l1 protein / protein interactions | |
MX2016013028A (es) | Compuestos utiles como inmunomoduladores. |